Biontech Se Sponsored Adr Stock News

BioNTech stock, a leader in messenger RNA technology and Pfizer's Covid-19 vaccine partner, declined by almost 31% over the last month, considerably underperforming the S&P 500 which remained roughly

South African Scientists Confirm Boosters Offer Little Protection From Omicron On Monday, a team of Israeli scientists publicized research showing that even a second booster dose of the Moderna or Pfizer mRNA vaccines doesn''t bestow complete immunity from the omicron variant. Now, just days later, their conclusion appears to have been corroborated by a team of South African researchers from the University of Cape Town and Stellenbosch University who observed seven individuals who had been infected with the omicron variant despite having been "boosted". The patients represented the first known cases of breakthrough infection by omicron, the researchers told the Lancet , the British medical journal where their findings were published. Keep in mind, the South African team used a very different approach. First of all, the patients they examined had only received a single booster dose (unlike with the Israeli study, which focused on patients who had received two doses). As for the study''s subjects, all of them were white, and four were participating in medical training at Cape Town hospitals.

Inflation is on fire, there are labor and supply shortages, and the Fed is hinting at multiple rate hikes. We'll look at how stocks can perform in this environment. In 2021, the market rose on low int

BioNTech SE Sponsored ADR (BNTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising ea

Regeneron (REGN), Vertex Pharmaceuticals (VRTX) and BioNTech (BNTX) are three large biotech stocks that are worth betting on in the current scenario.

Shares of vaccine makers, including Moderna Inc Full story available on Benzinga.com

A fourth dose of Pfizer and BioNTech''s Covid shot is only partly effective against omicron, according to a new test. The vaccine stocks fell.

Shares of BioNTech have fallen this morning following results from an Israeli study showing that a fourth COVID-19 shot is less effective against the Omicron variant than other strains.

Investors are weighing results from an Israeli study and recent comments from Moderna's CEO.

Could these biotech stocks be poised for gains in 2022?

Leading COVID-19 vaccine makers Pfizer (PFE)/BioNTech (BNTX), Moderna (MRNA), and Novavax (NVAX) are trading lower in the pre-market amid concerns that their efforts to

A fresh Supreme Court ruling does neither stock any favors.

Shares of vaccine makers, including Moderna Inc (NASDAQ:MRNA), BioNTech SE – ADR (NASDAQ:BNTX) and Novavax, Inc. (NASDAQ:NVAX), are all trading lower as the sector continues to pull back followi

The successful rollout of a revolutionary vaccine leaves the immunotherapy specialist primed for further gains.